Skip to main content

Table 2 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency 18 individuals identified by selective metabolic screening due to clinical symptoms (n = 17, no clinical details in n = 1)

From: 3-methylcrotonyl-CoA carboxylase deficiency: Clinical, biochemical, enzymatic and molecular studies in 88 individuals

Pt #

Sex

Ethnic origin

age at diagnosis

current age (y)

Biochemical phenotype

Carboxylase activities in fibroblasts (pmol/min/mg protein)1

Genotype

Clinical phenotype§

DBS/ plasma

urine

affected gene

Nucleotide change (at RNA level)

Amino acid change (predicted from RNA)

C5OH

3-HIVA

3MCG

MCC

PCC

Allele 1 Allele 2

30

m

Turkish

newborn

died at 33 days

++

++

++

0

637

MCCC2

c.1574+1G>A c.1574+1G>A

(p.F497Gfs*4) (p.F497Gfs*4)

acute decompensation on first day of life, acidosis, hypoglycaemia, hyperlactemia, hyperammonemia, encephalopathy, depressed neonatal reflexes, hypertonic episodes, prominent hypotonia, respiratory insufficiency requiring assisted ventilation, cardiac arrest, patient deceased on day 33

             

CT scan of the brain: multiple cysts, ventricular dilatation, cerebral atrophy

32a

m

Arab

4 years

14

++

++

++

5.0

863

MCCC2

c.127C>T c.127C>T

p.Q43* p.Q43*

muscular hypotonia, weakness, mild motor delay (fr)

35a

m

Caucasian

9 months

16

na

++

++

7.3

976

MCCC2

(exon 7 to 14 skipping) (exon 7 to 14 skipping)

(p.I209Pfs*43) (p.I209Pfs*43)

developmental delay, familial nystagmus, hyperopia, significant hand tremor, mild learning disability, failure to thrive, unpleasant odour descibed as "smelling like cat`s urine", hypothermia, ketonuria, hypoglycemia and mild hyperammonemia prior to stabilisation on dietary therapy (ltf, 3y)

36

f

Turkish

3 years

11

++

++

++

0.4

420

MCCC1

c.1527C>A c.1527C>A

p.C509* p.C509*

mental and speech retardation, spasticity, impaired physical performance (ltf)

42

f

Caucasian

?

24

++

++

++

0

664

MCCC2

c.929C>G c.929C>G

p.P310R p.P310R

severe muscular weakness, muscle pain (ltf, 16y)

44

m

Caucasian

1.5 years

10

na

++

++

4.0

425

MCCC2

c.463C>T c.463C>T

p.R155W p.R155W

psychomotor retardation, seizures, muscular hypotonia, metabolic stroke, failure to thrive, clinodactyly of the 5th fingers (fr)

50

f

Arab

13 years

21

na

++

++

8.1

761

MCCC1

c.1882G>T c.1114C>T

p.E628* p.Q372*

mild Reye-like episode and encephalitis during Influenza A infection at age 5 years, mild learning disability, severe attention-deficit hyperactivity disorder, multiple sclerosis (fr)

54

m

Asian

?

13

++

++

++

1.3

1162

MCCC1

c.980C>G c.639+2T>A

p.S327* p.S164Rfs*3

psychomotor retardation, attention deficit hyperactivity disorder, frequent skin picking behaviour (ltf)

60

f

Turkish

?

10

++

++

++

6.4

754

MCCC1

c.2079delA c.2079delA

p.V694* p.V694*

mild global psychomotor retardation, convulsions starting at the age of 18 months during febrile episode, continued as generalized tonic clonic seizures after the age of 3 years, nephrolithiasis, episodes of hematuria (ltf, 4 y)

63

m

Turkish

?

8

++

++

na

12.0

729

MCCC2

c.464G>A c.464G>A

p.R155Q p.R155Q

3 metabolic decompensations with encephalopathy, seizures, acidosis, hypoglycemia, mild developmental retardation

68

m

Turkish

3 years

9

++

++

++

2.4

335

MCCC1

c.1155A>C c.1155A>C

R385S R385S

severe metabolic decompensation with metabolic stroke, cerebral edema and hemiparesis, mild psychomotor retardation, seizures (fr)

77

m

Arab

8 months

9

na

++

++

0

777

MCCC2

c.463C>T c.463C>T

p.R155W p.R155W

psychomotor and speech retardation, kyphoscolisis, genu varum, hypogammaglobulinemia, chronic diarrhea, reversible cytopenia under TPN (ltf, 7y)

80

m

Turkish

1.5 years

9

++

++

n (6m)++ (1y)

22.8

1162

MCCC2

c.116C>T c.116C>T

p.S39F p.S39F

speech retardation, seizures, recurring attacks of status epilepticus (ltf, 3y)

89

f

Caucasian

7 months

10

na

na

na

17.0

986

MCCC2

(exon 8 to 10 skipping)

(p.K248_V334del)

failure to thrive, poor feeding (ltf, 5y)

           

(exon 8 to 10 skipping)

(p.K248_V334del)

 

92

m

Caucasian

1 week

5

++

++

++

na

na

MCCC2

c.710G>A c.1149+5G>C

p.G237D p.?

acute metabolic crisis, mild retardation (fr)

96a

m

Turkish

1 year

6

++

++

++

7.3

1212

MCCC1

c.873+ 4524_6787del2264

large deletion

acidosis at 1 year of age, atonic seizures starting at 1 year of age (fr)

           

c.873+ 4524_6787del2264

large deletion

 

99a

f

Turkish

8 years

died at 8 years

++

++

++

na

na

MCCC2

c.392G>T c.392G>T

p.C131F p.C131F

catecholaminergic ventricular tachycardia (mutation in RyR2 gene) sudden cardiac death at age 8 years

69

?

Arab

?

9

na

na

na

18.9

1210

MCCC2

c.1567A>G

p.S523G

?

           

c.1567A>G

p.S523G

 
  1. 1 control values measured in 53 cell lines, expressed as median value and (range): MCC activity, 305 pmol/min/mg protein (134-671); PCC activity, 583 (208-1165); ratio of PCC/MCC activity, 1.93 (1.19 – 2.58).
  2. § information in brackets: fr followed regularly, ltf lost to follow-up, age of last follow-up, if known. + slightly elevated; ++ massively elevated; C5OH 3-hydroxyisovalerylcarnitine; DBS dried blood spots; 3-HIVA 3-hydroxyisovaleric acid; 3-MCG 3-methylcrotonylglycine; f female; fr followed regularly; ltf lost to follow-up; m male; MCC methylcrotonyl-CoA carboxylase; n normal; na not available; NBS newborn screening; PCC propionyl-CoA carboxylase; Pt # Patient number; RNA nd RNA not detectable; SMS selective metabolic screening; y years; mutation heterozygous on genomic PCR, homozygous in RT-PCR; # diagnosed following the positive NBS result of their baby; ? not known.